Eli Lilly & Co. faces criminal probe into alleged manufacturing errors
Category: #headlines  | By Nikita Chaurasia  | Date: 2021-05-29 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly & Co. faces criminal probe into alleged manufacturing errors

The U.S. Department of Justice has reportedly launched a criminal probe into pharma company, Eli Lilly and Co., to investigate alleged irregularities in manufacturing, and tampering records at a plant that produces the company’s drugs including COVID-19 therapy medicines in Branchburg, New Jersey.

According to sources, the company has disclosed in a securities filing about a subpoena received from the Justice Department earlier this month, seeking documents about the Branchburg factory.

Eli Lilly stated that it is fully cooperating in the ongoing inquiry and had previously employed independent investigations to verify certain allegations relating to the Branchburg unit.

It is to be noted that the company had faced backlash in April when employees accused a factory administrator of altering FDA-required documents to cover up existing quality control issues. Eli Lilly had then revealed that none of the issues flagged by FDA authorities impacted the quality of medicine supplied to its customers, cited sources with knowledge of the matter.

If reports are to be believed, the Justice Department probe involving U.S. prosecutors and other authorities from New Jersey and Washington commenced in recent weeks, with inputs from the Federal Bureau of Investigation (FBI).

The former head of the FDA’s Office of Manufacturing and Product Quality, Steven Lynn, said that the federal government rarely seeks criminal charges arising from manufacturing violations unless those infractions are extremely serious and the company in question does little to fix them.

For the record, FDA officials had inspected the Branchburg plant in November 2019 and found that quality control data was deleted and not appropriately audited. They had returned in July to find several other quality control issues and flaws in manufacturing.

Meanwhile, the U.S. has put a pause on the shipment of Eli Lilly’s COVID-19 therapy drug - mAb combo, to the states of Oregon, Arizona, Florida, California, Indiana, and Washington, as the drug seems to be ineffective in treating the COVID—19 variants from Brazil and South Africa, now prevailing in these states.

Source Links –

https://whbl.com/2021/05/27/exclusive-u-s-opens-criminal-probe-into-alleged-lapses-at-eli-lilly-plant-sources/

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Shell trades off Russian retail business to native oil producer Lukoil

Shell trades off Russian retail business to native oil producer Lukoil

By Nikita Chaurasia

Energy giant Shell plans on selling more than 400 petrol stations of its Russian subsidiary Shell Neft to Lukoil, the second largest oil producer in the country after state backed Rosneft. As several Western oil and gas firms seek to get rid of th...

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

Mitsubishi, Siemens sign an MoU to cooperate in SiC traction technology

By Nikita Chaurasia

Mitsubishi Electric Europe and Siemens Mobility have recently signed a memorandum of understanding (MoU) to work together in silicon carbide (SiC) traction power technology. As per reports, JR Central’s next-generation N700S Shinkansen train...

Legato opens 80 new jobs in its Limerick Research & Development hub

Legato opens 80 new jobs in its Limerick Research & Development hub

By Nikita Chaurasia

The global capability center of a leading U.S. health care insurance company, Legato Health Technologies is planning to build an additional 80 posts at its Limerick facility. It would bring the total number of staff to 200, which the fir...